Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO5429083 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part A: RO5429083 | EXPERIMENTAL | - |
| Part B: RO5429083 + cytarabine | EXPERIMENTAL | - |
| A | EXPERIMENTAL | - |
| B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RO5429083 | DRUG | Multiple escalating doses |
| cytarabine | DRUG | 1000 mg/m2 iv daily for 5 consecutive days, up to 4 cycles |
Inclusion Criteria: * Adult patients, \>/= 18 years of age * Histologically or cytologically confirmed, acute myelogenous leukemia (all subtypes except acute promyelotic leukemia) according to WHO criteria * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 * All non-hematological...
RO5429083 is an investigational small molecule being studied for the treatment of acute myelogenous leukemia and other neoplasms, including metastatic and locally advanced malignant solid tumors. It is in Phase 1 clinical development by Roche Holding AG.
RO5429083 is being studied in patients with CD44-expressing malignant solid tumors. It is a small molecule developed for oncology indications, with clinical trials focusing on CD44-expressing tumors and acute myelogenous leukemia.
RO5429083 is being developed by Roche Holding AG, a biopharmaceutical company. The drug is in Phase 1 clinical trials for oncology indications, including acute myelogenous leukemia and other neoplasms.
RO5429083 is in Phase 1 clinical development. It is an investigational drug, not yet approved, and has completed Phase 1 trials in patients with acute myelogenous leukemia and with CD44-expressing malignant solid tumors.
RO5429083 has been studied in two completed Phase 1 trials. NCT01358903 evaluated the drug in patients with metastatic or locally advanced CD44-expressing malignant solid tumors. NCT01641250 studied it alone or with cytarabine in patients with acute myelogenous leukemia.
RO5429083 is the sole name used for this investigational drug in clinical trials. No alternative names have been reported for this compound in the available clinical trial information.